A Prospective, Multi-Center Study of the Conor Cobalt Chromium Reservoir Based Stent (NevoTM) With Sirolimus Elution in Native Coronary Artery Lesions (RES-ELUTION II).

Trial Profile

A Prospective, Multi-Center Study of the Conor Cobalt Chromium Reservoir Based Stent (NevoTM) With Sirolimus Elution in Native Coronary Artery Lesions (RES-ELUTION II).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2012

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Acute coronary syndromes; Angina pectoris; Coronary artery disease; Coronary artery restenosis; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms NEVO-RES-II; RES-ELUTION-II
  • Sponsors Conor Medsystems; Cordis Corporation
  • Most Recent Events

    • 01 Oct 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 Feb 2012 Additional lead trial investigator (Andrejs Erglis) identified as reported by ClinicalTrials.gov.
    • 12 Aug 2009 Trial acronym (NEVO-RES-II) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top